Trial Profile
Ondansetron Augmentation in Treatment-resistant OCD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2015
Price :
$35
*
At a glance
- Drugs Ondansetron (Primary)
- Indications Obsessive-compulsive disorders
- Focus Therapeutic Use
- 03 Mar 2011 New trial record